■ A first-in-human feasibility trial of SpyGlass Pharma’s drug-delivery platform demonstrated a 45% drop in mean IOP at 3 months, according to a news release. The platform consists of a single-piece, hydrophobic acrylic IOL with drug-eluting pads attached to the haptics. It is implanted into the capsular bag during cataract surgery and designed to deliver multiple years of bimatoprost to lower IOP in patients with glaucoma or ocular hypertension.

“The SpyGlass drug-delivery platform holds great promise for patients living with glaucoma,” said Malik Y. Kahook, MD, cofounder, president, and executive chairman of the board at SpyGlass Pharma. “Our innovative drug-delivery platform is designed to enable all cataract surgeons to provide unprecedented multiyear therapy to treat glaucoma and other chronic eye conditions at the time of routine cataract surgery. The initial data are compelling and demonstrate the potential of this new treatment paradigm to significantly improve patient management without compromises.”

In the trial, 23 patients undergoing cataract extraction were randomized to 1 of 3 doses of bimatoprost via the SpyGlass platform. After 3 months, mean reduction in IOP across all groups was 45%, and all patients achieved an IOP of ≤18 mmHg without need for additional therapy, according to a news release. No significant adverse events were reported, and visual outcomes were similar to those achieved with commercially available IOLs.

Editor’s note: The print edition of this news item included an error that has been corrected here and in the digital edition. The original version stated that, “all patients achieved an IOP of ≥18 mmHg or lower without need for additional therapy.” This has been corrected to read, “all patients achieved an IOP of ≤18 mmHg without need for additional therapy.” Glaucoma Physician regrets the error.